# Why a type 1 diabetes study measured C-peptide

- Article ID: research-249
- Product: Liraglutide (liraglutide-702)
- Canonical page: https://heritagebiolabs.com/research-library/articles/249-why-a-type-1-diabetes-study-measured-c-peptide
- Product collection: https://heritagebiolabs.com/research-library/products/liraglutide
- Product page: https://heritagebiolabs.com/product/liraglutide-702
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

A peptide is a short amino-acid chain whose links are peptide bonds. Some peptides act as signals, while others can be measured as clues to what a cell produces. Liraglutide is a modified GLP-1 receptor agonist peptide. Its effects on blood glucose in type 2 diabetes led researchers to ask a narrower question in people with long-standing type 1 diabetes. Could the medicine preserve any insulin-making function that remained? [1, 2]

When pancreatic beta cells make insulin, they split a precursor into insulin and a separate short chain called C-peptide. A C-peptide measurement can help researchers estimate how much insulin the body is making itself. The study enrolled 18 adults with type 1 diabetes who still had measurable fasting C-peptide. They were randomly assigned to liraglutide or placebo for 52 weeks. The investigators measured C-peptide after a standardized meal to see how the remaining beta cells responded to food. [1]

The primary outcome compared the change in stimulated C-peptide at week 52. The researchers did not find that liraglutide improved that outcome compared with placebo. They also examined results across several visits, including a visit after treatment ended, in an exploratory analysis. In that analysis C-peptide fell more steeply in the liraglutide group. Because the latter analysis was exploratory and the trial was very small, it provides a question for further study rather than a precise estimate of harm. [1]

This trial concerns residual beta-cell function in adults with long-standing type 1 diabetes. The U.S. Victoza label describes a type 2 diabetes indication for glycemic control. The groups and the biological questions differ. A change in HbA1c in type 2 diabetes would not tell researchers how much insulin a person with type 1 diabetes can still produce. By measuring C-peptide after a meal, the investigators directly tested the particular question that motivated their trial. [1, 2]

## Sources

1. J. Caballero-Corbalán et al. Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial. Diabetes, Obesity and Metabolism (publication 2026-08-13). <https://pubmed.ncbi.nlm.nih.gov/42595732/>
2. U.S. Food and Drug Administration. VICTOZA (liraglutide) injection, prescribing information. Drugs@FDA (publication 2025-10). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s046lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 050 - Lipopeptide and Liraglutide.docx; article 249; content SHA-256 2e02ed5d52b694edce9eba52c8ab8c2c12af2306fe22b9f0a36c2c0fe5bc4281.
